storage stability raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-26 and is reviewed periodically as new material appears.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
=== Other activity === Certain progestins have been found to stimulate the proliferation of MCF-7 breast cancer cells in vitro, an action that is independent of the classical PRs and is instead mediated via the progesterone receptor membrane component-1 (PGRMC1). Progesterone, nomegestrol acetate, and chlormadinone acetate act neutrally and do not stimulate proliferation, whereas norethisterone, desogestrel, levonorgestrel, and drospirenone strongly stimulate proliferation and medroxyprogesterone acetate, dienogest, and dydrogesterone weakly stimulate proliferation. As such, progesterone differs from some but not all progestins in the activity mediating this PGRMC1-dependent effect. It is unclear if these findings may explain the different risks of breast cancer observed with progesterone, dydrogesterone, and other progestins such as medroxyprogesterone acetate and norethisterone in clinical studies.
Suvorexant is approved for the treatment of insomnia by the United States Food and Drug Administration (FDA) at doses of 5 to 20 mg and by the Australian Therapeutic Goods Administration (TGA) and Japanese Pharmaceuticals and Medical Devices Agency (PMDA) at doses of 15 mg (in the elderly) and 20 mg (in younger adults). In the United States, the recommended starting dose is 10 mg and the maximum recommended dose is 20 mg. Higher doses of 30 and 40 mg were also submitted to regulatory agencies for approval but were not authorized due to lack of clearly superior efficacy to doses of 15 to 20 mg and concerns about next-day effects and associated impairment (e.g., driving). In addition to the preceding doses, suvorexant has been assessed at higher doses of up to 100 mg in clinical trials. These higher doses appeared to be more effective at promoting sleep than lower doses but produced greater next-day effects. Lower approved doses of suvorexant in the United States in the range of 5 to 10 mg were not extensively evaluated in clinical trials. The American Academy of Sleep Medicine's 2017 clinical practice guidelines recommend the use of suvorexant in the treatment of sleep-onset and sleep-maintenance insomnia along with various other sleep medications. Orexin receptor antagonists are not used as first-line treatments for insomnia due to their costs and concerns about possible misuse liability. Generic formulations of orexin receptor antagonists including suvorexant are not yet available.
== Development == The usual development of CAD is when a cool high-pressure area wedges in east of a north-south oriented mountain chain. As a system approaches from the west, a persistent cloud deck with associated precipitation forms and lingers across the region for prolonged periods of time. Temperature differences between the warmer coast and inland sections east of the terrain can exceed 36 degrees Fahrenheit (20 degrees Celsius), with rain near the coast and frozen precipitation, such as snow, sleet, and freezing rain, falling inland during colder times of the year. In the Northern Hemisphere, two-thirds of such events occur between October and April, with summer events preceded by the passage of a backdoor cold front. In the Southern Hemisphere, they have been documented to occur between June and November. Cold air damming events which occur when the parent surface high-pressure system is relatively weak, with a central pressure below 1,028.0 millibars (30.36 inHg), or remaining a progressive feature (move consistently eastward), can be significantly enhanced by cloudiness and precipitation itself. Clouds and precipitation act to increase sea level pressure in the area by 1.5 to 2.0 mb ( 0.04 to 0.06 inHg). When the surface high moves offshore, the precipitation itself can cause the CAD event.
==== Bapineuzumab ==== Bapineuzumab, a humanized anti-Aβ mAb, is directed against the N-terminus of Aβ. Phase II clinical trials of Bapineuzumab in mild to moderate AD patients resulted in reduced Aβ concentration in the brain. However, in patients with increased apolipoprotein (APOE) e4 carriers, Bapineuzumab treatment is also accompanied by vasogenic edema, a cytotoxic condition where the blood brain barrier has been disrupted thereby affecting white matter from excess accumulation of fluid from capillaries in intracellular and extracellular spaces of the brain. In Phase III clinical trials, Bapineuzumab showed promising positive effect on biomarkers of AD but failed to show effect on cognitive decline. Therefore, Bapineuzumab was discontinued after failing in the Phase III clinical trial.
== Diseases treated by endocrinologists == Diabetes mellitus: This is a chronic condition that affects how the body regulates blood sugar. There are two main types: type 1 diabetes, an autoimmune disease that occurs when the body attacks the cells that produce insulin; and type 2 diabetes, a condition in which the body either does not produce enough insulin or does not use it effectively. Thyroid disorders: These are conditions that affect the thyroid gland, a butterfly-shaped gland located in the front of the neck. The thyroid gland produces hormones that regulate metabolism, heart rate, and body temperature. Common thyroid disorders include hyperthyroidism (overactive thyroid) and hypothyroidism (underactive thyroid). Adrenal disorders: The adrenal glands are located on top of the kidneys. They produce hormones that help regulate blood pressure, blood sugar, and the body's response to stress. Common adrenal disorders include Cushing's syndrome (excess cortisol production) and Addison's disease (adrenal insufficiency). Pituitary disorders: The pituitary gland is a pea-sized gland located at the base of the brain. It produces hormones that control many other hormone-producing glands in the body. Common pituitary disorders include acromegaly (excess growth hormone production) and Cushing's syndrome (excess ACTH production). Metabolic disorders: These are conditions that affect how the body processes food into energy. Common metabolic disorders include obesity, high cholesterol, and gout.
Sources: en.wikipedia.org
Sphinxes are a feature of the neoclassical interior decorations of Robert Adam and his followers, returning closer to the undressed style of the grottesche. They had an equal appeal to artists and designers of the Romanticism and subsequent Symbolism movements in the 19th century. Most of these sphinxes alluded to the Greek sphinx and the myth of Oedipus, rather than the Egyptian, although they may not have wings. The Decadent Movement, a European movement that was attributed to the notion of "decadence" around the 1890s, implores the main notion of finding beauty in the decline of civilization in the form of macabre or taboo subjects such as the sphinx. The motif of the sphinx can also be connected to the motif of the "femme fatale" figure in decadent texts in which a typically female-like figure or beast seduces and murders men. The "femme fatale" is used to establish a decline or decay ranging from perversion, death, prostitution, and other taboos of Victorian society. Oscar Wilde, a known Decadent writer, utilized this motif in his poem "The Sphinx". The poem itself establishes a connection between the Sphinx and the French due to underlying social decline such as the French Empire collapsing. Wilde describes the sphinx as a sort of half-cat and half-woman that is connected to many mythological events, typically that of Egypt and Greece, as well as how the mysterious creature is surrounded by lust and death. The writer James Thomson, similarly to Wilde, also utilizes the motif of the sphinx in his poem "The City of Dreadful Night".
==== Non-deterministic wallet ==== In a non-deterministic wallet, each key is randomly generated independently and is not derived from a common seed. Therefore, any backups of the wallet must store each and every private key used as an address, as well as a buffer of future keys that may have already been issued as addresses but have not yet received payments.
The majority of historic territories whose land now lies within Lower Saxony were sub-principalities of the medieval, Welf estates of the Duchy of Brunswick-Lüneburg. All the Welf princes called themselves dukes "of Brunswick and Lüneburg" despite often ruling parts of a duchy that was forever being divided and reunited as various Welf lines multiplied or died out.
Paulovich is a Professor in Clinical Research, an Aven Foundation Endowed Chair, and the Director of Early Detection Initiative at the Fred Hutchinson Cancer Research Center. She was inducted to the American Society for Clinical Inviestigation in 2012. Paulovich is an expert in proteomics. Her targeted proteomics method uses multiple reaction monitoring mass spectrometry to target cancer biomarkers with ongoing clinical trials, and was named Method of the Year in 2012 by Nature Methods. She founded Precision Assays in 2016, whose rights to targeted assays were acquired by CellCarta in 2022. 2014 Life Science Innovation Northwest Woman to Watch in Life Science Award 2015 Human Proteome Organization (HUPO) Distinguished Achievement in Proteomic Sciences Award Identification and use of biomarkers for detection and quantification of the level of radiation exposure in a biological sample (2011) US 20130052668 A1 Compositions and methods for reliably detecting and/or measuring the amount of a modified target protein in a sample (2011) US 20130052669 A1
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.